Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2015

View Archived Issues

Boehringer Ingelheim starts phase I trial of BI-655130

Angiogenesis biomarkers are associated with adverse pregnancy outcomes in SLE and APL patients

Astellas Pharma describes prostanoid EP4 antagonists

Actelion Pharmaceuticals designs CRTH2 antagonists

Boehringer Ingelheim and Philogen to collaborate on trial of immunotherapy for AML

New phase II trial explores use of sevuparin in sickle cell disease

Bio-Path completes cohort 7 of phase Ib trial of Liposomal Grb-2 in AML

Lilly and Innovent Biologics expand their strategic alliance

New insights into ADHD

Acceleron's ACE-083 increases muscle preclinically, enters phase I study

Myriad Genetics validates pan-cancer genetic test using saliva

Loss-of-function mutations in TBK1 is associated with FTD and ALS

aTyr Pharma begins phase Ib/II trial for patients with limb girdle muscular dystrophy 2B

Takeda Pharmaceutical patents PKC theta inhibitors

Incyte and Merck & Co. to study the combination of epacadostat with Keytruda

The Vanderbilt University discloses Mcl-1 inhibitors

Piramal Enterprises develops retinoid ROR-gammaT antagonists

Torrent Pharmaceuticals reports MAPK14 inhibitors

Cinryze receives FDA fast track designation

Zavante announces formation of new company

PBI-4050 awarded E.U. orphan drug designation for IPF

Lassomycin kills M. tuberculosis by a two-fold mechanism

Sequenom and UKE to profile circulating tumor DNA in CRC

Novartis makes additional investment in Gamida Cell

PELI3 shows promise as a biomarker for SS-KCS

Addex Therapeutics reports efficacy of ADX-71441 in models of alcohol use disorder

Takeda and UCL partner to discover gene targets for neurodegenerative diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...